Tianjin Eleli Technology Development
Finnrick has tested 37 samples from Tianjin Eleli Technology Development across 5 products.
Take Action
Request Full Data Access to the Finnrick database of peptide tests.
Products
| Tests | ||||||||
|---|---|---|---|---|---|---|---|---|
| Product | Rating | Count | Avg | Min | Max | Oldest | Most Recent | |
| BPC-157 | 5 | 10 Feb 2026 | 12 Aug 2026 | |||||
| GHK-Cu | 6 | 11 Feb 2026 | 12 Aug 2026 | |||||
| Retatrutide | 16 | 26 Jan 2026 | 9 Aug 2026 | |||||
| Tesamorelin | 4 | 8 Feb 2026 | 15 Jul 2026 | |||||
| Tirzepatide | 6 | 29 Jan 2026 | 9 Aug 2026 | |||||
The Tianjin Eleli Technology Development samples tested by Finnrick were either acquired by Finnrick directly, or submitted by the public.
Customer Reviews
These indicators of customer satisfaction are based on reports submitted by the public through the Finnrick testing program, and are not verified.
Based on 38 overall satisfaction reports
People who submitted test requests to Finnrick gave Tianjin Eleli Technology Development an average satisfaction rating of 4.3 out of 5 across 38 reports associated with samples received and tested by Finnrick.
Most recent Tianjin Eleli Technology Development tests
Samples are tested in commercial labs
tests
products
Scores
First
Last
| Quantity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Test Date | Product | Certificate | Test Score | Label | Tested | Difference | Purity | Batch ID | Container | Tested At | Sent By |
| 12 Aug 2026 | BPC-157 | View | 10mg | 10.5mg | +5.0% | 92.20% | 8.B.06.08.26 | White label / Silver crimp / Clear cap | Lab E | Public | |
| 12 Aug 2026 | GHK-Cu | View | 50mg | 12.3mg | -75.4% | 79.30% | 4.B.04.26 | White label / Silver crimp / Blue cap | Lab E | Public | |
| 9 Aug 2026 | Tirzepatide | View | 30mg | ⚠️ Sample does not contain Tirzepatide | 11.B.04.03.26 | White label / Silver crimp / White cap | Lab G | Public | |||
| 9 Aug 2026 | BPC-157 | View | 10mg | 13.6mg | +36.0% | 99.70% | 6.B.05.26 | White label / Silver crimp / Blue cap | Lab G | Public | |
| 9 Aug 2026 | Retatrutide | View | 20mg | 20.8mg | +4.0% | 99.80% | 16.B03.26 | White label / Silver crimp / Violet cap | Lab G | Public | |
| 15 Jul 2026 | Tesamorelin | View | 10mg | ⚠️ Sample does not contain Tesamorelin | (no batch ID) | Silver label / Copper crimp / Clear cap | Lab G | Public | |||
| 13 Jul 2026 | Retatrutide | View | 20mg | 20.7mg | +3.5% | 99.80% | 03/31/26 | No label / Silver crimp / Violet cap | Lab E | Public | |
About Tianjin Eleli Technology Development Test Results From Finnrick
Tianjin Eleli Technology Development is a peptide vendor with multiple products tracked in the independent testing dataset collected by Finnrick. This page compiles recent, batch-level test results across 5 products and 37 tests, including scores, test dates, batch IDs, and lab details. This enables you to compare quality over time, not just marketing claims.
Each tested sample receives a 0–10 score, with 10 being the best possible value. It is the total of three components: purity (0–4 points), quantity accuracy vs. the label or batch claim (0–4 points), and batch information quality (0–2 points).
When several test results are available for a product and vendor pair, you’ll also find a Finnrick Rating (A–E, where A is best and E is worst, X if an insufficient number of tests is available, or F in rare cases of documented and widespread fraud) and customer satisfaction reports with sub-scores that provide additional context. Use the table above to review purity, quantity accuracy, consistency between batches, and any notable outliers surfaced in Finnrick testing data.
Tianjin Eleli Technology Development Testing Activity & Score Summary
In the past 30 days, Finnrick has published 5 new test results for Tianjin Eleli Technology Development, and 16 in the past three months. The overall dataset includes 37 tested samples with an average score of 5.8/10 across all products.
Across 37 identity-tested samples, 81% were confirmed to contain the expected peptide (identity pass rate). Among those that passed, median purity was 99.8%. Approximately 93% of passing samples tested at or above 98% purity.
Here is a closer look at the most frequently tested products (top 3):
- Retatrutide (16 tests, 81% identity pass, median purity 99.8%) — Test scores are highly variable, ranging from 0.0 to 10.0 (average 7.0/10), suggesting significant batch-to-batch differences.
- Tirzepatide (6 tests, 50% identity pass, median purity 99.2%) — Test scores are highly variable, ranging from 0.0 to 7.8 (average 3.6/10), suggesting significant batch-to-batch differences.
- GHK-Cu (6 tests, 100% identity pass, median purity 99.9%) — Test scores are highly variable, ranging from 3.1 to 7.6 (average 5.2/10), suggesting significant batch-to-batch differences.